13-Mar-2014 - Preclinical CRO Charles River Labs has announced plans to buy discovery services firms Argenta and BioFocus from Galapagos NV.
10-Mar-2014 - In a sign of further consolidation, CRO INC Research has acquired CRO MEK Consulting and will absorb its more than 40 employees based in the Middle East and north Africa.
26-Feb-2014 - DSM has reported modest growth in its pharma business as a shareholders advisory firm comes out in favour of the upcoming merger with Patheon.
24-Feb-2014 - CRO consolidation has left market opportunities for providers who serve mid-size pharma, UK-based private equity firm Cinven says as it acquires Medpace.
24-Feb-2014 - Icon says it intends to continue its M&A strategy focusing on capabilities, geographies and technologies as it reports a robust 2013.
19-Feb-2014 - Mid-tier pharma mergers and a shift to more complex trials will benefit broad-based CROs, whilst smaller outsourcing partners will be forced to consolidate, an industry report by Citi Research predicts.
12-Feb-2014 - Charles River Laboratories says it will shutter a Research Models and Services (RMS) facility in Michigan as softened demand for the sector offset a strong year for its preclinical service...
03-Feb-2014 - CROs CTI Trial and Clinical Consulting recently acquired Community Research, David Blume, managing director of Edgemont Capital, told us.
30-Jan-2014 - Catalent has filed an initial public offering (IPO) with the SEC to raise $100m though this could reach upwards of $500m, according to one investment firm.
30-Jan-2014 - Asia’s leading small-molecule CRO GVK BIO will acquire the capital stock of US-based CRO Aragen Bioscience.
20-Jan-2014 - Strategic relationships with both big pharma and mid-tier firms will drive future growth, says Charles River laboratories (CRL).
14-Jan-2014 - Whether McKesson will relaunch its bid to acquire German logistics firm Celsio has been questioned by analysts after the proposed $8.3bn (€6.1bn) takeover bid fell through.
09-Jan-2014 - Merck Millipore has sold its Discovery and Development Solutions (DDS) Business to Eurofins saying it was unable to fully support.
08-Jan-2014 - Patheon is the world’s largest pharmaceutical development services (PDS) provider and third largest contract manufacturer, according to a report released yesterday.
02-Jan-2014 - Cyprotex has bought CeeTox in a bid to diversify its revenue base beyond its core pharmaceutical preclinical services business.
19-Dec-2013 - A private equity investor has sold its stake in CRO Chiltern leading to a restructured ownership the firm says will encourage expansion.
12-Dec-2013 - Algorithme Pharma has increased early stage patient access by teaming with a Montreal hospital, and says it provides a breadth of therapeutic areas not normally associated with mid-sized CROs.
10-Dec-2013 - Venn Life Sciences has purchased Belfast, UK CRO Medevol in its second acquisition in as many months.
03-Dec-2013 - Soon to merge CMO Patheon has increased solid dosage form production capacity at its site in the UK and posted an improved set of preliminary results for the financial year.
02-Dec-2013 - Strategic partnerships are “the next phase” of sponsor-CRO relations, according to Parexel, and on top of saving pharma on oversight costs will reshape the industry.
02-Dec-2013 - Private equity will be looking to exit the CRO industry and could pose a threat to recent strong growth, according to financial experts at PCT
02-Dec-2013 - Trust, transparency and end-to-end participation are just some of the reasons Merck Serono says its exclusive strategic partnership with Quintiles is the “first of its kind.”
18-Nov-2013 - Venn Life Sciences has broadened its global footprint with the acquisition of a German CRO and says it is looking for more growth opportunities.
13-Nov-2013 - US CRO PRA International has announced plans to buy privately-owned early phase trial specialist CRI Lifetree.
29-Oct-2013 - inVentiv Health has opened a new UK office in order to better target European customers, whilst Novum says its North Dakota facility will strengthen its offerings.